Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of YL202 in selected advanced solid tumors
CTR20253821Phase 2Active
- Sponsor
- MediLink Therapeutics
- Start
- Sep 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of YL202 in Non-small cell lung cancer (NS-NSCLC), Cervical Cancer (CC), colorectal cancer (CRC), Nonhematologic neoplasms, sponsored by MediLink Therapeutics. Started Sep 2025; status: active.
02
Drugs
YL202
03
Conditions
Non-small cell lung cancer (NS-NSCLC)Cervical Cancer (CC)colorectal cancer (CRC)Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20253821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253821.